Spero Therapeutics, Inc. (SPRO) Operating cash flow 2016–2025
Spero Therapeutics, Inc. (SPRO) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$12.6MFY2025 · since FY2016: -$29.0M → -$12.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$12.6M | +46.2% |
| FY2024 | -$23.4M | +28.9% |
| FY2023 | -$33.0M | -326.8% |
| FY2022 | -$7.7M | +88.0% |
| FY2021 | -$64.3M | +25.1% |
| FY2020 | -$85.9M | -71.7% |
| FY2019 | -$50.0M | -26.2% |
| FY2018 | -$39.6M | -1.3% |
| FY2017 | -$39.1M | -35.1% |
| FY2016 | -$29.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice